At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 175 enrolled
Drug / intervention
CIN-107drug
Likely dose
CIN-107 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107
In Brief
A Phase 2 clinical trial evaluating CIN-107 for Hypertension. Completed, enrolled 175 participants across 36 sites.
Detailed Summary
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedJul 2022
Primary CompletionNov 2023
TodayJul 2026
First PostedJul 15, 2022
Enrollment StartApr 6, 2022
Primary CompletionNov 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.0 years ago
Interventions
CIN-107drug
2 mg of CIN-107, once a day for 52 weeks